Arcutis Biotherapeutics Inc. Common Stock (ARQT)

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selec…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

354

Website

arcutis.com/

Fundamentals

1-day range

$23.74$24.88

Market cap

$3.24B

P/E (trailing)

113.86

P/E (forward)

18.25

EPS (trailing)

$0.21

Dividend yield

—

Beta

1.58

Avg. volume

1.68M

Forecasts

8 analyst ratings

Arcutis Biotherapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.24BP/E 113.86
  $15.1$31.77
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.21BP/E —
  $23.05$42.21
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.33BP/E —
  $3.76$31.35
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.39BP/E —
  $6.28$12.5
• MBX

  MBX Biosciences Inc. Common Stock

  $63.04

  ▼ 5.05%
  Market cap $3.07BP/E —
  $9.63$72.64
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.44BP/E —
  $18.26$94.9
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.53BP/E —
  $14.79$62.32

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K
  Benzinga · 8/25/2026
• Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum
  ChartMill · 8/24/2026
• Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
  benzinga · 8/20/2026
• Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
  Benzinga · 8/20/2026
• Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup
  ChartMill · 8/19/2026
• Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals
  ChartMill · 8/14/2026
• Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup
  ChartMill · 8/11/2026
• Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
  Benzinga · 8/6/2026
• Arcutis Biotherapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026

• Terrie Curran · August 27, 2026 · Option Exercise

  27.1K @ $8.63
• Terrie Curran · August 27, 2026 · Option Exercise

  11.1K @ $7.51
• Terrie Curran · August 27, 2026 · Sale

  27.1K @ $25.03
• Terrie Curran · August 27, 2026 · Sale

  11.1K @ $25.03
• Terrie Curran · August 20, 2026 · Option Exercise

  1.1K @ $7.51
• Terrie Curran · August 20, 2026 · Sale

  1.1K @ $26.04
• Patrick Burnett · August 12, 2026 · Option Exercise

  6.7K @ $3.64
• Patrick Burnett · August 12, 2026 · Sale

  6.7K @ $26.08
• Patrick Burnett · August 11, 2026 · Option Exercise

  8.3K @ $3.64
• Patrick Burnett · August 11, 2026 · Sale

  8.3K @ $26.52
• Masaru Matsuda · August 3, 2026 · Sale

  1.2K @ $26.12
• Watanabe Todd · August 3, 2026 · Sale

  4.4K @ $26.12
• Patrick Burnett · August 3, 2026 · Sale

  955 @ $26.12
• Howard G. Welgus · July 15, 2026 · Option Exercise

  2.3K @ $8.63
• Howard G. Welgus · July 15, 2026 · Option Exercise

  1.0K @ $7.51

Institutional Ownership

March 31, 2026

Total shares held

129.13M

Total value held

$3.00B

Institutional holders

257